RF
Richard D Francis
President and CEO

Richard D Francis insider trades: Teva Pharmaceutical Industries (TEVA) stock buys and sales

President and CEO, Teva Pharmaceutical Industries Last trade Jun 5, 2026 25 Form 4 filings
$31.3M
Sold, last 12 months
5 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2017
2
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Richard reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 5, 2026TEVA↓ Sell$211K
Mar 5, 2026TEVA↓ Sell$634K
Mar 4, 2026TEVA↓ Sell$759K
Mar 3, 2026TEVA↓ Sell$14.3M
Feb 15, 2026TEVA↓ Sell$15.3M
Mar 5, 2025TEVA↓ Sell$376K
Mar 4, 2025TEVA↓ Sell$503K
Feb 18, 2025TEVA↓ Sell$1.3M
Mar 4, 2024TEVA↓ Sell$414K
Feb 15, 2024TEVA↓ Sell$980K
Nov 17, 2017MTD↑ Buy$100K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other TEVA insiders

Open-market trades in the last 12 months

About Richard D Francis's insider trades

Richard D Francis is President and CEO at Teva Pharmaceutical Industries (TEVA). Since Nov 17, 2017, Richard has reported 1 open-market purchase worth $100K and 10 sales worth $34.8M on SEC Form 4. In the last 12 months: 5 sales ($31.3M).

Their filings also include grants and awards (16 filings), option exercises (10 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TEVA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.